Status: Recruiting
Prospective Pharmacogenetic Cohort Study of CYP2D6 Metabolizer Phenotype, Analgesic Failure, and Adverse Effects in Postoperative Patients Receiving Tramadol by Elastomeric Infusion Pump
This prospective pharmacogenetic cohort will enroll postoperative patients receiving a standardized tramadol-containing elastomeric analgesia pump. CYP2D6 genotype will be measured but will not determine treatment during the 72-hour study window. Participants with non-normal metabolizer phenotypes will be compared with normal metabolizers for analgesic treatment failure and adverse effects. Pain, rescue medication, pump discontinuation, sedation, respiratory status, nausea/vomiting, and other adverse events will be assessed at prespecified times.
Participants needed: 200
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Research IncUpdated: Sep 9, 2026Locations: 1Duration: 1 Month
Eligibility criteria
Elective surgery followed by the institution's standardized tramadol-containing... [+3]
Known tramadol allergy or contraindication. [+5]